Egypt vs Senegal: HIV/AIDS deaths averted by antiretroviral therapy
Egypt
2,035 deaths
in 2024
Senegal
2,002 deaths
in 2024
Egypt rank
56th
Senegal rank
57th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Egypt
- Senegal
How they compare
Egypt currently reports 2,035 deaths against 2,002 deaths in Senegal, a difference of 33 deaths.
The two have swapped places 5 times across 35 shared years of data; in 1990 it was Senegal ahead.
Egypt ranks 56th and Senegal ranks 57th of 157 countries.
Senegal has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Egypt | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 23.89 deaths | 481.41 deaths | 457.52 deaths | Senegal |
| 2010s | 346.74 deaths | 1,757 deaths | 1,410 deaths | Senegal |
| 2020s | 1,477 deaths | 1,992 deaths | 514.64 deaths | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Egypt or Senegal?
- Egypt, at 2,035 deaths against 2,002 deaths in Senegal as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Egypt and Senegal?
- 33 deaths, with Egypt ahead.
- How many years of comparable data are there for Egypt and Senegal?
- 35 years are reported by both, from 1990 to 2024.
- How do Egypt and Senegal rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Egypt ranks 56th and Senegal ranks 57th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.